Delstrigo pill image


DOR/3TC/TDF doravirine/lamivudine/tenofovir disoproxil fumarate

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily without regard to food for people taking HIV treatment for the first time (treatment-naïve) or individuals with suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to components of the regimen: doravirine, lamivudine, or tenofovir. Tablet contains 100 mg of the NNRTI doravirine plus 300 mg lamivudine and 300 mg tenofovir DF (TDF). Approved only for adults at this time.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney problems; Delstrigo is not recommended for people with estimated creatinine clearance less than 50 mL/min. Should not be used by people with moderate or severe kidney impairment or severe liver impairment.
  • See the individual drugs contained in Delstrigo: Pifeltro, Epivir, and Viread.
  • See package insert for more complete information on potential side effects and interactions.


Merck & Co.
(800) 672-6372



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments